Top-News

Merus Aktie News

Aktie
WKN:  A2AKFX ISIN:  NL0011606264 US-Symbol:  MRUS Branche:  Biotechnologie Land:  Niederlande
82,00 €
-0,50 €
-0,61%
10:44:13 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,71 Mrd. €
Streubesitz
-
KGV
-13,92
Index-Zuordnung
-

Merus News

21.11.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-​MRUS, ACLS, VECO, and CLCO PR Newswire
17.11.25 - PR Newswire
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab PR Newswire
12.11.25 - PR Newswire
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
05.11.25 - PR Newswire
Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
04.11.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - MRUS, HSII, PRO, and PBBK
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - MRUS, HSII, PRO, and PBBK PR Newswire
24.10.25 - GlobeNewswire
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
– 100% response rate in 1L left-​sided mCRC (n=8, confirmed and unconfirmed)
21.10.25 - PR Newswire
Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders
Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders PR Newswire
21.10.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS PR Newswire
14.10.25 - GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile
13.10.25 - GlobeNewswire
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET
03.10.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders PR Newswire
30.09.25 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) PR Newswire
29.09.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, HFWA, TIPT on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, HFWA, TIPT on Behalf of Shareholders PR Newswire
29.09.25 - wallstreetONLINE Redaktion
41 Prozent im Plus: Milliarden-Deal: Diese Aktie explodiert!
Im Biotech-​Sektor steht eine Milliardenübernahme an. Genmab übernimmt mit Merus einen Krebsmittelspezialisten, der zuletzt ein vielversprechendes Blockbuster-​Medikament ...
07.08.25 - GlobeNewswire
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung
– Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses ...
05.08.25 - GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 6 3% response rate observed among 43 evaluable patients and 79% ...
05.06.25 - GlobeNewswire
Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein ...
05.06.25 - GlobeNewswire
Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein ...
04.06.25 - GlobeNewswire
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology ...
03.06.25 - GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology ...

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »